RANCHO CORDOVA, Calif., Aug. 10 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. , a leading supplier of innovative products for processing and storing adult stem cells, said today that Hal Baker has joined the Company as Vice President, Sales, effective immediately.
Mr. Baker has more than two decades of global sales and marketing experience in the healthcare sector, introducing new products, leading teams in the cord blood stem cell market, managing distributor relationships and building sales force organizations.
Most recently, Mr. Baker was Vice President, Global Sales, for Hygenic Corporation, a global manufacturer and marketer of over the counter pain relievers, rehabilitation consumables and OEM specialty products for the medical and dental markets. Before that, he was Senior Vice President, U.S. Commercial Operations, and Senior Vice President, Global Marketing, for Pall Corporation, a $2 billion filtration and separation products manufacturer serving the life science and industrial markets.
Mr. Baker spent four years as Director, Global Marketing, for Gambro Healthcare, a provider of automated blood and stem cell collection technologies. Before that, he held senior sales and marketing management positions with two medical device companies, U.S. Medical Instruments and IVAC Corporation. He holds a B.A. in Political Science from Miami University of Ohio, and a Master’s in Political Science from Kent State University.
“We are fortunate to have someone of Hal’s background and experience joining ThermoGenesis at this important time in the Company’s development,” said J. Melville Engle, Chief Executive Officer of ThermoGenesis. “Hal has a strong record of executing successful sales strategies, new product launches and market expansion initiatives, and he has extensive experience in both the cord blood and stem cell sectors.
“We have exciting opportunities, not only with our BioArchive(R) Systems and AXP(R) AutoXpress(TM) (“AXP”) offerings for the cord blood market, but also with our initiatives in the bone marrow sector through our MXP(TM) MarrowXpress(TM) System (“MXP”), and the recently introduced Res-Q(TM) 60 BMC (“Res-Q”) System that address the point of care market,” Engle added.
Last week, ThermoGenesis announced the launch of the Res-Q System, an automated cell processing system for the concentration of bone marrow-derived stem cells at the point of care, and an expanded collaboration for the Res-Q and MXP with Celling Technologies, a subsidiary of SpineSmith, LLC, a leading distributor of orthopedic products. The MXP is a microprocessor-controlled device and a dedicated single-use disposable bag set for concentrating stem cells. The bone marrow concentrates collected by the MXP are used in spinal fusion procedures.
“I am delighted to be joining ThermoGenesis as the Company continues to progress on its turnaround strategy. I look forward to working with Mel and other members of the management team in developing and implementing an effective sales strategy and capitalizing on new market opportunities for the Company’s current and future offerings,” Mr. Baker said.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers’ purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers’ products, introduction timing and acceptance of our new products scheduled for fiscal years 2009 and 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption “Risk Factors” in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
SOURCE ThermoGenesis Corp.
CONTACT: ThermoGenesis Corp., Investor Relations, +1-916-858-5107,
ir@thermogenesis.com
Web site: http://www.thermogenesis.com/
